Linking EHRs with genomic profiling data from patients with NSCLC supported associations seen in clinical trials.
This first-in-human trial will enroll up to 24 patients.
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
“Most men with early-stage prostate cancer will die with their disease, not from their disease,” Dr Murphy said.
Future studies will look at combining the therapy with anti-PD1 blockade.
There are no biomarkers that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib.
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
The continuous decline in cancer deaths over the past 25 years was attributed to improvements in screening, treatment.
Experts examined the role of population-based early detection cancer screening.
Breast cancer models showed certain neoadjuvant chemotherapy promoted prometastatic behavior.
